VESICARE 1 mg/ml, oral suspension bottle, 150 ml
Active ingredients: Solifenacin, Solifenacin succinate
Commercialized according to BDPMDispensing in France: Prescription only
Oral suspensionbottle, 150 mlorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VESICARE 1 mg/ml, suspension buvable
- Pharmaceutical form
- suspension buvable
- Route of administration
- orale
- Presentation description
- 1 flacon(s) jaune(brun) polytéréphtalate (PET) avec fermeture de sécurité enfant de 150 ml
- Marketing authorisation holder
- ASTELLAS PHARMA
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 1 Jun 2019
- Prescription and dispensing conditions
- Prescription only
- List II: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60608174CIP73003664CIP133400930036648Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SUCCINATE DE SOLIFÉNACINEsuspension | 1 mg · 1 ml de suspension buvable | SA |
| SOLIFÉNACINEsuspension | 0,75 mg · 1 ml de suspension buvable | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.